优先审评-话题@MedSci

#优先审评#

46篇内容 | 1031人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1634790, encodeId=b43c1634e900f, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=SMO抑制剂上市申请获CDE优先审评，治疗基底细胞癌, objectType=article, longId=208132, objectId=72842081322b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72842081322b, replyNumber=0, likeNumber=57, createdTime=2021-08-04, rootId=0, userName=ms5822920152752585, userId=4be222283241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72842081322b, moduleTitle=SMO抑制剂上市申请获CDE优先审评，治疗基底细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72842081322b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634789, encodeId=f9e31634e89b3, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=百时美施贵宝血液病创新药Luspatercept上市申请获CDE优先审评, objectType=article, longId=206759, objectId=7050206e59ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7050206e59ba, replyNumber=0, likeNumber=47, createdTime=2021-07-06, rootId=0, userName=ms5822920152752585, userId=4be222283241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7050206e59ba, moduleTitle=百时美施贵宝血液病创新药Luspatercept上市申请获CDE优先审评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7050206e59ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634792, encodeId=b82c1634e9299, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=纳入优先审评！恒瑞医药创新药吡咯替尼新适应症——新辅助治疗, objectType=article, longId=217708, objectId=bfcd21e7083b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfcd21e7083b, replyNumber=0, likeNumber=34, createdTime=2021-12-16, rootId=0, userName=ms5822920152752585, userId=4be222283241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfcd21e7083b, moduleTitle=纳入优先审评！恒瑞医药创新药吡咯替尼新适应症——新辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfcd21e7083b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634778, encodeId=8c8c1634e7841, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=FDA优先审评多肽-药物偶联物（PDC）Melflufen治疗难治性多发性骨髓瘤的申请, objectType=article, longId=200078, objectId=465a2000e861, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=465a2000e861, replyNumber=0, likeNumber=35, createdTime=2020-12-14, rootId=0, userName=ms5822920152752585, userId=4be222283241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=465a2000e861, moduleTitle=FDA优先审评多肽-药物偶联物（PDC）Melflufen治疗难治性多发性骨髓瘤的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=465a2000e861)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634785, encodeId=1d731634e85e6, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=迭代达菲？罗氏抗流感病毒新药玛巴洛沙韦片上市申请纳入拟优先审评, objectType=article, longId=202925, objectId=17a520292554, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17a520292554, replyNumber=0, likeNumber=38, createdTime=2021-08-12, rootId=0, userName=ms5822920152752585, userId=4be222283241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17a520292554, moduleTitle=迭代达菲？罗氏抗流感病毒新药玛巴洛沙韦片上市申请纳入拟优先审评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17a520292554)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634784, encodeId=8c611634e846f, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=第3批临床急需境外用药！罗氏「玛巴洛沙韦片」在华上市申请拟纳入优先审评, objectType=article, longId=202909, objectId=5e7320290908, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e7320290908, replyNumber=0, likeNumber=34, createdTime=2021-06-11, rootId=0, userName=ms5822920152752585, userId=4be222283241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e7320290908, moduleTitle=第3批临床急需境外用药！罗氏「玛巴洛沙韦片」在华上市申请拟纳入优先审评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e7320290908)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634791, encodeId=a5221634e9187, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=2次接种有效率达96%-99％，辉瑞森林脑炎疫苗获FDA优先审评, objectType=article, longId=208141, objectId=9ad620814163, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ad620814163, replyNumber=0, likeNumber=40, createdTime=2021-05-21, rootId=0, userName=ms5822920152752585, userId=4be222283241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ad620814163, moduleTitle=2次接种有效率达96%-99％，辉瑞森林脑炎疫苗获FDA优先审评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ad620814163)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634780, encodeId=48a31634e80cf, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=国内申报上市的第二个CAR-T疗法获“优先审评+突破性药物”双重审评资格, objectType=article, longId=200548, objectId=626120054831, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=626120054831, replyNumber=0, likeNumber=47, createdTime=2021-07-18, rootId=0, userName=ms5822920152752585, userId=4be222283241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=626120054831, moduleTitle=国内申报上市的第二个CAR-T疗法获“优先审评+突破性药物”双重审评资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=626120054831)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634786, encodeId=ec8a1634e86c5, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=阿斯利康达格列净治疗慢性肾病适应症获FDA优先审评资格, objectType=article, longId=205578, objectId=ddb72055e8b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddb72055e8b9, replyNumber=0, likeNumber=51, createdTime=2021-07-26, rootId=0, userName=ms5822920152752585, userId=4be222283241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddb72055e8b9, moduleTitle=阿斯利康达格列净治疗慢性肾病适应症获FDA优先审评资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddb72055e8b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634777, encodeId=63b51634e77c5, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=中国新药上市申请，阿斯利康宣布用于治疗非小细胞肺癌的沃利替尼获得优先审评, objectType=article, longId=198346, objectId=d324198346a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d324198346a0, replyNumber=0, likeNumber=46, createdTime=2020-11-10, rootId=0, userName=ms5822920152752585, userId=4be222283241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d324198346a0, moduleTitle=中国新药上市申请，阿斯利康宣布用于治疗非小细胞肺癌的沃利替尼获得优先审评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d324198346a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634783, encodeId=45431634e83ac, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=早期肺癌辅助治疗！奥希替尼新适应症上市申请获FDA优先审评资格, objectType=article, longId=202884, objectId=423720288436, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=423720288436, replyNumber=0, likeNumber=38, createdTime=2021-05-20, rootId=0, userName=ms5822920152752585, userId=4be222283241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=423720288436, moduleTitle=早期肺癌辅助治疗！奥希替尼新适应症上市申请获FDA优先审评资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=423720288436)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634776, encodeId=0a4f1634e76b2, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=国家药监局优先审评审批，新一代国产肺癌创新药上市, objectType=article, longId=193935, objectId=19e91939353f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19e91939353f, replyNumber=0, likeNumber=38, createdTime=2021-01-11, rootId=0, userName=ms5822920152752585, userId=4be222283241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19e91939353f, moduleTitle=国家药监局优先审评审批，新一代国产肺癌创新药上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19e91939353f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634788, encodeId=f6121634e8857, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=奥拉帕利新适应症上市申请拟纳入优先审评，治疗前列腺癌, objectType=article, longId=206130, objectId=192220613074, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=192220613074, replyNumber=0, likeNumber=36, createdTime=2021-02-24, rootId=0, userName=ms5822920152752585, userId=4be222283241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=192220613074, moduleTitle=奥拉帕利新适应症上市申请拟纳入优先审评，治疗前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=192220613074)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634787, encodeId=c74a1634e8711, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=治疗14天，1型糖尿病风险降低59%！突破性疗法teplizumab获FDA优先审评资格, objectType=article, longId=205577, objectId=44252055e715, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44252055e715, replyNumber=0, likeNumber=48, createdTime=2021-06-27, rootId=0, userName=ms5822920152752585, userId=4be222283241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44252055e715, moduleTitle=治疗14天，1型糖尿病风险降低59%！突破性疗法teplizumab获FDA优先审评资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44252055e715)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634781, encodeId=baea1634e81c1, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=皮下注射PD-L1在中国申报上市，拟优先审评, objectType=article, longId=200936, objectId=f3b920093688, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3b920093688, replyNumber=0, likeNumber=39, createdTime=2021-03-28, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3b920093688, moduleTitle=皮下注射PD-L1在中国申报上市，拟优先审评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3b920093688)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634779, encodeId=71fd1634e79be, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=基石药业RET抑制剂普拉替尼中国上市申请获受理并纳入优先审评, objectType=article, longId=200377, objectId=e4512003e762, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4512003e762, replyNumber=0, likeNumber=33, createdTime=2020-09-17, rootId=0, userName=ms5822920152752585, userId=4be222283241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4512003e762, moduleTitle=基石药业RET抑制剂普拉替尼中国上市申请获受理并纳入优先审评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4512003e762)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634782, encodeId=9b931634e829f, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=豪森药业1类乙肝新药「艾美酚胺替诺福韦片」申报上市，拟优先审评, objectType=article, longId=200943, objectId=904a20094367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=904a20094367, replyNumber=0, likeNumber=48, createdTime=2021-01-16, rootId=0, userName=ms5822920152752585, userId=4be222283241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=904a20094367, moduleTitle=豪森药业1类乙肝新药「艾美酚胺替诺福韦片」申报上市，拟优先审评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=904a20094367)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634774, encodeId=4a101634e741f, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=Keytruda第二个“不限癌种”上市申请获FDA优先审评, objectType=article, longId=191931, objectId=6cef19193185, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cef19193185, replyNumber=0, likeNumber=62, createdTime=2020-12-16, rootId=0, userName=ms5822920152752585, userId=4be222283241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cef19193185, moduleTitle=Keytruda第二个“不限癌种”上市申请获FDA优先审评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cef19193185)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634773, encodeId=87311634e73e9, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=又有抗癌新药来了！礼来Verzenio、安进Blincyto被纳入优先审评, objectType=article, longId=184663, objectId=917318466353, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=917318466353, replyNumber=0, likeNumber=39, createdTime=2020-11-06, rootId=0, userName=ms5822920152752585, userId=4be222283241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=917318466353, moduleTitle=又有抗癌新药来了！礼来Verzenio、安进Blincyto被纳入优先审评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=917318466353)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634775, encodeId=99da1634e754c, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, objectTitle=再鼎医药新型抗生素——奥玛环素上市申请获NMPA优先审评, objectType=article, longId=193902, objectId=a4ea193902d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4ea193902d3, replyNumber=0, likeNumber=43, createdTime=2020-06-18, rootId=0, userName=ms5822920152752585, userId=4be222283241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4ea193902d3, moduleTitle=再鼎医药新型抗生素——奥玛环素上市申请获NMPA优先审评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4ea193902d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

优先审评

2020-05-29

ms5822920152752585 (审核中...)

前往app查看评论内容

#优先审评#

SMO抑制剂上市申请获CDE优先审评，治疗基底细胞癌

2021-08-04

ms5822920152752585 (审核中...)

前往app查看评论内容

#优先审评#

百时美施贵宝血液病创新药Luspatercept上市申请获CDE优先审评

2021-07-06

ms5822920152752585 (审核中...)

前往app查看评论内容

#优先审评#

纳入优先审评！恒瑞医药创新药吡咯替尼新适应症——新辅助治疗

2021-12-16

ms5822920152752585 (审核中...)

前往app查看评论内容

#优先审评#

FDA优先审评多肽-药物偶联物（PDC）Melflufen治疗难治性多发性骨髓瘤的申请

2020-12-14

ms5822920152752585 (审核中...)

前往app查看评论内容

#优先审评#

迭代达菲？罗氏抗流感病毒新药玛巴洛沙韦片上市申请纳入拟优先审评

2021-08-12

ms5822920152752585 (审核中...)

前往app查看评论内容

#优先审评#

第3批临床急需境外用药！罗氏「玛巴洛沙韦片」在华上市申请拟纳入优先审评

2021-06-11

ms5822920152752585 (审核中...)

前往app查看评论内容

#优先审评#

2次接种有效率达96%-99％，辉瑞森林脑炎疫苗获FDA优先审评

2021-05-21

ms5822920152752585 (审核中...)

前往app查看评论内容

#优先审评#

国内申报上市的第二个CAR-T疗法获“优先审评+突破性药物”双重审评资格

2021-07-18

ms5822920152752585 (审核中...)

前往app查看评论内容

#优先审评#

阿斯利康达格列净治疗慢性肾病适应症获FDA优先审评资格

2021-07-26

ms5822920152752585 (审核中...)

前往app查看评论内容

#优先审评#

中国新药上市申请，阿斯利康宣布用于治疗非小细胞肺癌的沃利替尼获得优先审评

2020-11-10

ms5822920152752585 (审核中...)

前往app查看评论内容

#优先审评#

早期肺癌辅助治疗！奥希替尼新适应症上市申请获FDA优先审评资格

2021-05-20

ms5822920152752585 (审核中...)

前往app查看评论内容

#优先审评#

国家药监局优先审评审批，新一代国产肺癌创新药上市

2021-01-11

ms5822920152752585 (审核中...)

前往app查看评论内容

#优先审评#

奥拉帕利新适应症上市申请拟纳入优先审评，治疗前列腺癌

2021-02-24

ms5822920152752585 (审核中...)

前往app查看评论内容

#优先审评#

治疗14天，1型糖尿病风险降低59%！突破性疗法teplizumab获FDA优先审评资格

2021-06-27

仁者大医 (审核中...)

前往app查看评论内容

#优先审评#

皮下注射PD-L1在中国申报上市，拟优先审评

2021-03-28

ms5822920152752585 (审核中...)

前往app查看评论内容

#优先审评#

基石药业RET抑制剂普拉替尼中国上市申请获受理并纳入优先审评

2020-09-17

ms5822920152752585 (审核中...)

前往app查看评论内容

#优先审评#

豪森药业1类乙肝新药「艾美酚胺替诺福韦片」申报上市，拟优先审评

2021-01-16

ms5822920152752585 (审核中...)

前往app查看评论内容

#优先审评#

Keytruda第二个“不限癌种”上市申请获FDA优先审评

2020-12-16

ms5822920152752585 (审核中...)

前往app查看评论内容

#优先审评#

又有抗癌新药来了！礼来Verzenio、安进Blincyto被纳入优先审评

2020-11-06

ms5822920152752585 (审核中...)

前往app查看评论内容

#优先审评#

再鼎医药新型抗生素——奥玛环素上市申请获NMPA优先审评

2020-06-18

科室
- - 订阅+
  - 更多科室
工具
服务